Dake Benjamin T's Form 4 filing
Jade Biosciences, Inc. (JBIO) · filed Feb 8, 2023
- Accession no.
- 0001415889-23-002170
- Filed
- Feb 8, 2023
- Trade date
- Feb 6-7, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 5 derivative transactions. Open-market sales total $252.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dake Benjamin TCIK 0001869248 | Officer (SEE REMARKS) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 6, 2023 | Common Stock | MOption exerciseAcquired | +2,412 | $1.74 | +$4,196.88 | 2,412 | Direct | |
| Feb 6, 2023 | Common Stock | MOption exerciseAcquired | +7,872 | $2.14 | +$16,846.08 | 10,284 | Direct | |
| Feb 6, 2023 | Common Stock | SSaleDisposed | −8,858 | $24.52F2 | −$217,198.16 | 1,426 | Direct | |
| Feb 6, 2023 | Common Stock | SSaleDisposed | −1,426 | $25.02F3 | −$35,678.52 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 6, 2023 | Common Stock | MOption exerciseDisposed | −905 | $0.00 | $0 | 9,961 | Direct | |
| Feb 6, 2023 | Common Stock | MOption exerciseDisposed | −1,507 | $0.00 | $0 | 27,122 | Direct | |
| Feb 6, 2023 | Common Stock | MOption exerciseDisposed | −1,019 | $0.00 | $0 | 26,478 | Direct | |
| Feb 6, 2023 | Common Stock | MOption exerciseDisposed | −6,853 | $0.00 | $0 | 191,871 | Direct | |
| Feb 7, 2023 | Common Stock | AGrant or awardAcquired | +62,000 | $0.00 | $0 | 62,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.95 to $24.92, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.96 to $25.155, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
Officer Title: President, Chief Operating Officer and Secretary